Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer - Takeaways - MDSpire

Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer

  • By

  • Manas Ranjan Sahu

  • Venu Akkanapally

  • Partha Sarathi Dasgupta

  • Sujit Basu

  • May 28, 2026

Share

  • 1

    Current anti-angiogenic therapies lack dynamic biomarkers for patient selection, leading to suboptimal outcomes and significant toxicities.

  • 2

    The DRD2–VEGF-A feedback loop in tumors allows for targeted anti-angiogenesis, offering a precision theranostic platform.

  • 3

    DRD2 agonists like cabergoline selectively inhibit tumor angiogenesis while preserving normal vascular integrity.

  • 4

    VEGF-A activates DRD2 expression in tumor endothelial cells, creating a self-regulating feedback loop that suppresses vascular permeability.

  • 5

    The proposed 'Dopaminergic Challenge' uses DRD2 agonists to assess tumor VEGF-dependency, enabling real-time treatment optimization.

Original Source(s)

Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer

  • by Manas Ranjan Sahu, Venu Akkanapally, Partha Sarathi Dasgupta, Sujit Basu

  • May 28, 2026

Related Content

Advanced Brain Tumor Care, Close to Home

  • by

  • May 28, 2026

  • 2 min
TAILORx and RxPONDER Trials Shift to a Discovery Platform

The ECOG-ACRIN Cancer Research Group, in collaboration with the SWOG Cancer Research Network, has launched a new initiative to analyze paired original and recurrent tumor specimens from two practice-c...

Roving Reporter Asks: Where Is Real Progress Being Made in Manufacturing and Supply Chain?

IBTV speaks with industry leaders at Advanced Therapies London 2026 to explore how automation, AI, closed systems, and smarter supply chain models are helping advanced therapies move toward scalable delivery

  • May 28, 2026

  • 1 min